Global Diabetic Retinopathy Market Report 2026: Outlook on Opportunities & Challenges

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Diabetic Retinopathy Market Size Growth Potential?
The diabetic retinopathy market size has grown strongly in recent years. It will grow from $9.26 billion in 2025 to $9.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing diabetes prevalence, late diagnosis of retinal damage, limited screening access, rising vision impairment cases, dependence on hospital-based eye care.

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $13.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growth of ai-assisted screening tools, expansion of ophthalmology clinics, increasing anti-vegf therapy adoption, focus on preventive eye care, rising aging diabetic population. Major trends in the forecast period include rising adoption of retinal screening programs, increased use of anti-vegf therapies, expansion of early detection and monitoring, growing integration of AI-based retinal imaging, rising focus on vision preservation.

Claim your free report sample now:
Diabetic Retinopathy Market Report 2026, Share And Insights Sample

What Are the Critical Growth Contributors in the Diabetic Retinopathy Market?
The rising prevalence of diabetes is expected to propel the growth of the diabetic retinopathy market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. The rise in the prevalence of diabetes is mainly driven by overweight, obesity, genetics, and physical inactivity, whereas patients with diabetes have too much sugar in their blood, which can damage the retina, which is part of the eye that detects light and sends signals to your brain through a nerve in the back of eye. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. The proportion of people meeting target HbA1c levels also reached 37.9%, the highest ever recorded by the National Diabetes Audit. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic retinopathy market.

How Is the Diabetic Retinopathy Market Mapped Across Its Segment Categories?
The diabetic retinopathy market covered in this report is segmented –

1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery
3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization, Vitreous Hemorrhage, Tractional Retinal Detachment
2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR, Moderate NPDR, Severe NPDR

What Are the Emerging Market Trends That Companies Should Monitor in Diabetic Retinopathy Market?
Major companies operating in the diabetic retinopathy market are focused on partnerships to increase their profitability in the market. Partnerships in diabetic retinopathy refer to collaborative efforts between various stakeholders, such as healthcare providers, researchers, pharmaceutical companies, and advocacy groups, to address the challenges associated with diabetic retinopathy. For instance, in October 2023, AEYE Health, a US-based provider of AI-based diagnostics for retinal imaging collaborated with Topcon Screen, a Japan-based diabetic screening platform. The goal of their collaboration is to provide point-of-care screening for diabetic retinopathy using artificial intelligence, ensuring swift and precise results, so that primary care clinicians can directly conduct diabetic retinopathy screenings in their clinics. This approach aims to reduce the chances of non-compliance and address care gaps associated with diabetic retinopathy screening by offering immediate, accurate assessments at the point of care.

Which Are the Major Market Players in the Diabetic Retinopathy Industry?
Major companies operating in the diabetic retinopathy market are Pfizer Inc., F-Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, Clearside Biomedical Inc.

Get the full diabetic retinopathy market report here:
Diabetic Retinopathy Market Report 2026, Share And Insights

Which Regions Are Forecasted to Experience the Fastest Growth in the Diabetic Retinopathy Market?
North America was the largest region in the diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

#Contact Us:#

The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

#Follow Us On:#

LinkedIn: The Business Research Company | LinkedIn